ipilimumab

1. 22:15
   x.com

   HRQoL After Induction Ipilimumab + Nivolumab and Bladder-Sparing Chemoradiotherapy in #MIBC: Phase 2 INDIBLADE Trial. Presented by Jan-Jaap Mellema @NKI_nl. #ESMO26 written coverag

1. 22:13
   x.com

   Could genetic testing help personalize melanoma treatment?
2. 19:45
   Lancet

   Disease-free survival and overall survival after neoadjuvant immunotherapy in mismatch repair-deficient colon cancer in the Netherlands: results of the single-arm, multicentre, phase 2, NICHE-2 trial.

   At the data cutoff of June 19, 2026, the single-arm, multicentre phase 2 NICHE-2 trial showed that neoadjuvant ipilimumab plus nivolumab in locally advanced mismatch repair-deficient colon cancer achieved a 3-year disease-free survival of 100% (97.5% CI 100-100) and an exploratory 5-year overall survival of 100% (95% CI 100-100).

Heat now 11·Peak in the comparable set 19 (Oct 23 23:00)·Change over 24h in the comparable set +158%·Participants now 3

Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.